Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee

Cancer

Volumn 86, Issue 2, 1999, Pages 349-363

  Shimada, Hiroyuki ^a   Ambros, Inge M ^b   Dehner, Louis P ^c   Hata, Jun Ichi ^d   Joshi, Vijay V ^e   Roald, Borghild ^f  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c BARNES JEWISH HOSPITAL   (United States)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HARTFORD HOSPITAL   (United States)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Classification; Ganglioneuroblastoma; Ganglioneuroma; Morphology; Neuroblastic tumors; Neuroblastoma; Pathology; Schwannian stroma

Indexed keywords

ARTICLE; CANCER REGRESSION; DIAGNOSTIC APPROACH ROUTE; GANGLIONEUROMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MEDICAL SOCIETY; NEUROBLASTOMA; NOMENCLATURE; PRIORITY JOURNAL; PROGNOSIS; SCHWANN CELL; TISSUE PREPARATION; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

BIOMETRY; BRAIN NEOPLASMS; GANGLIONEUROBLASTOMA; GANGLIONEUROMA; HUMANS; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; TERMINOLOGY;

EID: 0033565296     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.0.CO;2-Y     Document Type: Article

References (58)

1. Brodeur GM, Castleberry RP. Chapter 29: Neuro-blastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 3rd edition. Philadelphia: Lippincott-Raven, 1997:761-97.
2. Shimada H. Tumors of the neuroblastoma group. In: Williams R, editor. Pathology: state of the art reviews. Philadelphia: Hanley & Belfus, Inc., 1993;2:43-59.
3. Cushing H, Wolbach SB. Transformation of malignant paravertebral sympathicoblastoma into benign ganglioneuroma. Am J Pathol 1927;3:203-16.
4. D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favorable prognosis. Lancet 1971;1:1046-9.
5. Haas D, Albin AR, Miller C, Zoger S, Matthay KK. Complete pathologic maturation and regression of stage IV-S neuroblastoma without treatment. Cancer 1988;62:818-25.
6. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989;7:236-44.
7. Kushner BH, Cheung NV, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla M, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996;14:373-81.
8. Dehner LP. Peripheral and central primitive neuroectodermal tumors: a nosologic concept seeking a consensus. Arch Pathol Lab Med 1986;110:997-1005.
9. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993;12: 4481-7.
10. Brodeur GM, Pritchard J, Berthold F, Carlsen NLT, Castel V, Castleberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
11. Shimada H, Ambros I, Dehner LP, Hata J, Joshi W, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:363-71.
12. Ross JA, Severson RK, Pollock BH, Robison LL. Childhood cancer in the United States: a geographical analysis of cases from the Pediatric Cooperative Clinical Trials Group. Cancer 1996;77:201-7.
13. Monforte-Munoz H, Kawakami T, Stram D, Gerbing R, Matthay KA, Lukens J, et al. Neuroblastoma in children over 5 years of age: recognition of a rare and aggressive subset with "unconventional" morphology. Mod Pathol 1997;10:4P.
14. Hamburger V. History of the discovery of neuronal death in embryos. J Neurobiol 1992;23:1116-23.
15. Oppenheim RW. Naturally occurring cell death during neural development. Trends Neurosci 1985:487-93.
16. Levi-Montalcini R, Angeletti PU. Nerve growth factor. Physiol Rev 1968;48:534-69.
17. Turkel S, Itabashi HH. The natural history of neuroblastic cells in the fetal adrenal gland. Am J Pathol 1974;76:225-44.
18. Cooper MJ, Hutchins GM, Cohen PS, Helman LJ, Mennie RJ, Israel MA. Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. Cell Growth Diff 1990;1:149-58.
19. Beckwith JB, Perrin EV. In-situ neuroblastoma: its contribution to the natural history of neural crest tumors. Am J Pathol 1963;43:1089-104.
20. Bolande RP. A natural immune system in pregnancy serum lethal to human neuroblastoma cells: a possible mechanism for spontaneous regression. Perspect Pediatr Pathol 1992;16: 120-33.
21. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of mRNA for trk protooncogene and low affinity nerve growth factor in neuroblastoma with favorable prognosis. Cancer Res 1993;53:2044-50.
22. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-55.
23. Kaneko Y, Kanda N, Maseki N, Sakurai M, Tsuchida Y, Takeda T, et al. Different karyotypic patterns in early and advanced stage neuroblastoma. Cancer Res 1987;47:311-8.
24. Hayashi Y, Inaba T, Hanada R, Yamada M, Nakagome Y, Yamamoto K. Similar chromosomal patterns and lack of N-myc gene amplification in localized and IV-S stage neuroblastomas in infants. Med Pediatr Oncol 1989;17:111-5.
25. Bourhis J, Dominoci C, McDowell H, Raschella G, Wilson G, Castello MA, et al. N-myc genomic content and DNA ploidy in stage IV-S neuroblastoma. J Clin Oncol 1991;9:1371-5.
26. Grosfeld JL, Rescorla FJ, West KW, Goldman J. Neuroblastoma in the first year of life: clinical and biologic factors influencing outcome. Semin Pediatr Surg 1993;2:37-46.
27. Kogner P, Barbany G, Bjork O, Castello MA, Donfrancesco A, Falkmer UG, et al. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors. Prog Clin Biol Res 1994; 385:137-45.
28. Ambros PF, Ambros IM, Strehl S, Bauer S, Luegmayr A, Kovar H, et al. Regression and progression in neuroblastoma: does genetics predict tumour behaviour? Eur J Cancer 1995;31A:510-5.
29. Loretz W. Ein Fall von gangliosem Neurom (Gangliom). Arch Pathol Anat Physiol Klin Med 1870;49:435-7.
30. Martius K. Maligner Sympathoblastentumor des Halssympathikus, teilweise ausdifferenziert zu gutartigem Ganglioneurom. Frankfurt Zeitschr für Path 1913;xii:442-61.
31. Freund P. Ein Ganglioneurom des rechten Halssympathikus. Frankfurt Zeitschr f̈r Path 1913;xiii:266-77.
32. Dunn JS. Neuroblastoma and ganglioneuroma of the suprarenal body. J Pathol Bacterial 1915;xix:455-73.
33. Grosfeld JL, Skinner MA, Rescorla FJ, West KW, Scherer LR. Mediastinal tumors in children: experience with 196 cases. Ann Surg Oncol 1994;1:121-7.
34. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, et al. Successful treatment for stage III neuroblastoma based on prospective biologic staging: a Childrens Cancer Group study. J Clin Oncol 1998;16:1256-64.
35. Ambros IM, Zellner A, Roald B, Amann G, Ladenstein R, Printz D, et al. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med 1996;334:1505-11.
36. Reynolds ML, Woolf CJ. Reciprocal Schwann cell-axon interactions. Curr Opin Neurobiol 1993;3:683-93.
37. Shimada H, Chatten J, Newton WA, Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-16.
38. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224:1121-4.
39. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
40. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castelberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
41. Hayashi Y, Kanda N, Inaba T, Hanada R, Nagahara N, Muchi H, et al. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 1989;63:126-32.
42. Caron H, Van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, et al. Allelic loss of chromosome 1p as a predictor of unfavourable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30.
43. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas [review]. Eur J Cancer 1995;31A:505-10.
44. Joshi W, Cantor AB, Altshuler A, Larkin EW, Neill JSA, Shuster JJ, et al. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas: a clinical pathologic study of 211 cases from the Pediatric Oncology Group. Cancer 1992;69:2197-211.
45. Joshi W, Rao PV, Cantor AB, Altshuler G, Shuster JJ, Castleberry RP. Modified histologic grading of neuroblastoma by replacement of mitotic rate with mitotic karyorrhectic index: a clinicopathologic study of 223 cases from the Pediatric Oncology Group. Cancer 1996;77:1582-8.
46. Joshi W, Cantor AB, Altshuler A, Larkin EW, Neill JSA, Shuster JJ, et al. Recommendation for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification: a clinicopathologic study of 213 cases. Cancer 1992;69:2183-96.
47. Joshi W, Silverman JF, Altshuler A, Cantor AB, Larkin EW, Neil JSA, et al. Systematization of primary histopathologic and fine-needle aspiration cytologic features and description of unusual histopathologic features of neuroblastic tumors: a report from the Pediatric Oncology Group. Hum Pathol 1993;24:493-504.
48. Schmidt ML, Salwen HR, Chagnovich D, Bauer KD, Crawford SE, Cohn SL. Evidence for molecular heterogeneity in human ganglioneuroblastoma. Pediatr Pathol 1993;13:787-96.
49. Joshi W, Chatten J, Sather HN, Shimada H. Evaluation of Shimada classification in advanced neuroblastoma with special reference to the mitosis karyorrhexis index: a report from the Children's Cancer Study Group. Mod Pathol 1991; 4:139-47.
50. Shimada H, Stram DO, Chatten J, Joshi W, Hachitanda Y, Brodeur GM, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995;87:1470-6.
51. Wenzel A, Cziepluch C, Hamann U, Schurmann J, Schwab M. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max (p20/22) in human neuroblastoma cells. EMBO J 1991;10:3703-12.
52. Bursch W, Liehr JG, Sirbasku DA, Putz B, Taper H, Schulte-Hermann R. Control of cell death (apoptosis) by diethylstil-bestrol in an estrogen-dependent kidney tumor. Carcinogenesis 1991;12:855-60.
53. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
54. Coffin CM, Jaszcz W, O'Shea PA, Dehner LP. So-called congenital-infantile fibrosarcoma: does it exist and what is it? Pediatr Pathol 1994;14:133-50.
55. Brodeur GM, Hayes FA, Green AA, Casper JT, Wasson J, Wallach S, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987;47:4248-53.
56. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;4:581-91.
57. Beck D, De Bernardi B, Michon J, Ambros PF, Ambros IM, Foot A, et al. Phase II clinical trial of surgery as the only treatment for INSS stage 2 neuroblastoma (94.01 trial and study of the localized neuroblastoma study group; SIOP 95.01 study). Med Pediatr Oncol 1995;25:278.
58. Ambros PF, Ambros IM, Benard J, Caron H, Favrot M, Delattre O, et al. Application and definition of biological criteria to allow a refined treatment of localised neuroblastoma - as part of the LNESG protocol. Med Pediatr Oncol 1995;25:278.